Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Role of ET-1 in Microvascular Dysfunction Following GDM
NCT06547619Phase 1Recruiting
- Start
- Oct 2024
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1 trial of insulin aspart in endothelial dysfunction (4 arms). Primary endpoint: Amount of microvascular insulin-mediated dilation at 4 hours. Started Oct 2024; status: recruiting.
02
Drugs
insulin aspart
03
Conditions
endothelial dysfunction
Beyond the preview
Go deeper on NCT06547619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547619.